The pyrogen testing market in North America is anticipated to grow at a CAGR of 12.1% from 2023 to 2028 and the North American market size is expected to grow from USD 328.3 million in 2023 to USD 581.2 million by 2028.
The growing number of people suffering from infectious diseases requiring the rapid involvement of pyrogen analysis of the patient is one of the factors propelling the pyrogen testing market in North America. This is essential to ensure the safety of parenteral pharmaceuticals and medical devices, which further prevents life-threatening febrile reactions. In addition, the rise in outsourcing activities, the requirement for rapid approval of medical products and services through various tests, and the critical strategy of developing and launching new products adopted by the manufacturers to maintain their dominance and secure their position in the market are favoring the market in North America.
Furthermore, the growing focus on key market participants on research and developments and increased usage of technological advancements to develop and launch new products are accelerating the growth rate of the pyrogen testing market in North America. Fierce competition between the market players and the strategies by the companies to gain a competitive edge further propel the market growth. Growing awareness around pyrogen testing and increasing efforts of pharmaceutical and medical device companies regarding the toxicity present in drugs and medical devices are further escalating the market’s growth rate.
However, the presence of pre-existing advanced technologies in the North American region makes it harder for new players posing to be a drawback. Furthermore, large regional companies can only afford the high cost and high capital investment of these testing devices, R&D, and manufacturing, leaving the developing countries behind. This is foreseen to obstruct market growth. Moreover, more focus on other alternatives to pyrogen testing methods by most of the pharmaceutical companies due to non-specific results obtained, mainly from RPT, which are also inherently qualitative, along with lack of healthcare services is some of the factors which are further foreseen to hamper the growth of the pyrogen testing market in the region of North America.
This research report on the North American pyrogen testing market has been segmented and sub-segmented into the following categories:
By Test Type:
Geographically, North America had the most significant share of the global market in 2022. Growing investments in R&D from pharmaceutical and biotechnology players are one of the major factors contributing to the growth of the pyrogen testing market in North America. YOY growth in the number of people who have Cancer is another factor promoting market growth. Moreover, it has been reported by CDC that the primary cause of death in this region is a chronic disease, which is highly prevalent among the population, recorded in 6 in 10 adults in the United States. This chronic disease rise is expected to drive market growth over the forecast period. In addition, high expenditures on biopharmaceutical and pharmaceutical research, high prevalence of infectious diseases, increasing drug approvals, and its high application in testing used by pharmaceutical, biotechnology, and various drug manufacturing companies are some of the other factors further helping the market grow.
In the United States, the market for pyrogen testing is expected to grow significantly over the forecast period. This is primarily due to the US-based companies' emphasis on research and development, which has led to an increase in the use of pyrogen testing due to increased demand for the same, leading to an increase in the demand for devices doctors use for these testing devices as a result of the increasing preference for the continuous requirement of test kits and reagents. These factors are overall anticipated to be responsible for driving the pyrogen testing market growth across the region of North America over the forecast period.
The Canadian market is anticipated to grow at a steady CAGR during the forecast period. Due to the growing consumer demand for increased safety as well as the fact that pyrogenicity testing, which was previously done in rabbits with limited sensitivity and precision, has become one of the standard requirements for approval of medical products, manufacturers are focusing on the safe introduction of infection-free products to market through R&D activities.
KEY MARKET PLAYERS:
A few of the prominent companies operating in the North American pyrogen testing market profiled in this report are Associates of Cape Cod, Inc., Lonza Group, Merck Kgaa, Thermo Fisher Scientific, Ellab A/S, Genscript, Hyglos GmbH, Charles River Laboratories, Inc., Wako Chemicals USA, Inc., and WUXI Pharmatech (Cayman) Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com